- Home
- SENEB vs VERA Comparison
SENEB vs VERA Comparison
Compare SENEB & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- VERA
- Stock Information
- Founded
- SENEB 1949
- VERA 2016
- Country
- SENEB United States
- VERA United States
- Employees
- SENEB N/A
- VERA N/A
- Industry
- SENEB Packaged Foods
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- VERA Health Care
- Exchange
- SENEB Nasdaq
- VERA Nasdaq
- Market Cap
- SENEB 703.0M
- VERA 2.0B
- IPO Year
- SENEB N/A
- VERA 2021
- Fundamental
- Price
- SENEB $101.56
- VERA $23.82
- Analyst Decision
- SENEB
- VERA Buy
- Analyst Count
- SENEB 0
- VERA 8
- Target Price
- SENEB N/A
- VERA $64.63
- AVG Volume (30 Days)
- SENEB 580.0
- VERA 1.4M
- Earning Date
- SENEB 08-07-2025
- VERA 08-07-2025
- Dividend Yield
- SENEB N/A
- VERA N/A
- EPS Growth
- SENEB N/A
- VERA N/A
- EPS
- SENEB 5.90
- VERA N/A
- Revenue
- SENEB $1,578,887,000.00
- VERA N/A
- Revenue This Year
- SENEB N/A
- VERA N/A
- Revenue Next Year
- SENEB N/A
- VERA N/A
- P/E Ratio
- SENEB $16.97
- VERA N/A
- Revenue Growth
- SENEB 8.25
- VERA N/A
- 52 Week Low
- SENEB $57.51
- VERA $18.53
- 52 Week High
- SENEB $107.99
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- SENEB 61.21
- VERA 52.93
- Support Level
- SENEB $101.00
- VERA $22.57
- Resistance Level
- SENEB $94.02
- VERA $24.58
- Average True Range (ATR)
- SENEB 0.45
- VERA 1.22
- MACD
- SENEB 0.22
- VERA 0.14
- Stochastic Oscillator
- SENEB 58.86
- VERA 69.80
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.